c-met inhibitor compound-a (Amgen)
90
Structured Review
Amgen
c-met inhibitor compound-a
C Met Inhibitor Compound A, supplied by Amgen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/c-met+inhibitor+compound-a/c+met+inhibitors/pm32318883-127-33-26
Average 90 stars, based on 1 article reviews
C Met Inhibitor Compound A, supplied by Amgen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/c-met+inhibitor+compound-a/c+met+inhibitors/pm32318883-127-33-26
Average 90 stars, based on 1 article reviews
c-met inhibitor compound-a - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
Activation Assay:Article Title: Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and eliminates metastasis Article Snippet: It has been shown to be well tolerated by the mice (1, 2). iv) Ci group: c-MET inhibitor, Compound-A, is a small molecule inhibitor that prevents the activation of Article Title: Dasatinib Treatment Increases Sensitivity to c-Met Inhibition in Triple-Negative Breast Cancer Cells. Article Snippet: Acknowledgments: We would like to acknowledge Article Title: Targeting c-Met in triple negative breast cancer: preclinical studies using the c-Met inhibitor, Cpd A. Article Snippet: Introduction Triple negative breast cancer (TNBC) represents a heterogeneous subtype of breast cancer that carries a poorer prognosis.. There remains a need to identify novel drivers of TNBC, which may represent targets to treat the disease. c-Met overexpression is linked with decreased survival and is associated with the basal subtype of breast cancer.. Cpd A, a kinase inhibitor selective/specific for Met kinase has demonstrated preclinical anti-cancer efficacy in TNBC. Modification:Article Title: Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and eliminates metastasis Article Snippet: It has been shown to be well tolerated by the mice (1, 2). iv) Ci group: c-MET inhibitor, Compound-A, is a small molecule inhibitor that prevents the activation of Article Title: Dasatinib Treatment Increases Sensitivity to c-Met Inhibition in Triple-Negative Breast Cancer Cells. Article Snippet: Acknowledgments: We would like to acknowledge Article Title: Targeting c-Met in triple negative breast cancer: preclinical studies using the c-Met inhibitor, Cpd A. Article Snippet: Introduction Triple negative breast cancer (TNBC) represents a heterogeneous subtype of breast cancer that carries a poorer prognosis.. There remains a need to identify novel drivers of TNBC, which may represent targets to treat the disease. c-Met overexpression is linked with decreased survival and is associated with the basal subtype of breast cancer.. Cpd A, a kinase inhibitor selective/specific for Met kinase has demonstrated preclinical anti-cancer efficacy in TNBC. Cell Culture:Article Title: Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and eliminates metastasis Article Snippet: It has been shown to be well tolerated by the mice (1, 2). iv) Ci group: c-MET inhibitor, Compound-A, is a small molecule inhibitor that prevents the activation of Article Title: Dasatinib Treatment Increases Sensitivity to c-Met Inhibition in Triple-Negative Breast Cancer Cells. Article Snippet: Acknowledgments: We would like to acknowledge Article Title: Targeting c-Met in triple negative breast cancer: preclinical studies using the c-Met inhibitor, Cpd A. Article Snippet: Introduction Triple negative breast cancer (TNBC) represents a heterogeneous subtype of breast cancer that carries a poorer prognosis.. There remains a need to identify novel drivers of TNBC, which may represent targets to treat the disease. c-Met overexpression is linked with decreased survival and is associated with the basal subtype of breast cancer.. Cpd A, a kinase inhibitor selective/specific for Met kinase has demonstrated preclinical anti-cancer efficacy in TNBC. |
